Search

Your search keyword '"Gaidar, Ekaterina"' showing total 14 results
Start Over Author "Gaidar, Ekaterina"
14 results on '"Gaidar, Ekaterina"'

1. BCD020 rituximab bioanalog compared to standard treatment in juvenile systemic lupus erythematosus: The data of 12 months case-control study

Author

Kalashnikova, Elvira, primary, Isupova, Eugenia, additional, Gaidar, Ekaterina, additional, Sorokina, Lyubov, additional, Kaneva, Maria, additional, Masalova, Vera, additional, Dubko, Margarita, additional, Kornishina, Tatiana, additional, Lubimova, Natalia, additional, Kuchinskaya, Ekaterina, additional, Chikova, Irina, additional, Raupov, Rinat, additional, Kalashnikova, Olga, additional, and Kostik, Mikhail, additional

Published
2024
Full Text
View/download PDF

2. OA03 Are there any differences in the outcomes of treatment of a 12-month course of rituximab BCD020 biosimilar in systemic lupus erythematosus in children with early and late administration of the drug

Author

Kalashnikova, Elvira, primary, Rinat, Raupov, additional, Lubimova, Natalia, additional, Ekaterina, Kuchinskaya, additional, Isupova, Eugeniya, additional, Gaidar, Ekaterina, additional, Masalova, Vera, additional, Snegireva, Lyudmila, additional, Kornishina, Tatyana, additional, Sorokina, Lyuobov, additional, Kaneva, Mariya, additional, Kalashnikova, Olga, additional, Burtseva, Tatiana, additional, Argunova, Vera, additional, Sleptsova, Polina, additional, Chasnyk, Vyacheslav, additional, and Kostik, Mikhail, additional

Published
2023
Full Text
View/download PDF

3. Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study

Author

Kostik, Mikhail, primary, Kalashnikova, Elvira, additional, Rinat, Raupov, additional, Isupova, Eugenia, additional, Gaidar, Ekaterina, additional, Soloviev, Anton A., additional, Masalova, Vera, additional, Snegireva, Ludmila, additional, Kornishina, Tatyana, additional, Abramova, Natalia, additional, Suspitsin, Evgeny, additional, Sorokina, Lubov, additional, Kaneva, Maria, additional, Dubko, Margarita F., additional, Lubimova, Natalia, additional, Kuchuinskaya, Ekaterina, additional, Kalashnikova, Olga, additional, and Chasnyk, Vyacheslav, additional

Published
2023
Full Text
View/download PDF

4. Uveitis Is a Risk Factor for Juvenile Idiopathic Arthritis' Significant Flare in Patients Treated With Biologics

Author

Kostik, Mikhail M., primary, Gaidar, Ekaterina V., additional, Sorokina, Lubov S., additional, Avrusin, Ilya S., additional, Nikitina, Tatiana N., additional, Isupova, Eugenia A., additional, Chikova, Irina A., additional, Korin, Yuri Yu., additional, Orlova, Elizaveta D., additional, Snegireva, Ludmila S., additional, Masalova, Vera V., additional, Dubko, Margarita F., additional, Kalashnikova, Olga V., additional, and Chasnyk, Vyacheslav G., additional

Published
2022
Full Text
View/download PDF

5. The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience

Author

Kostik, Mikhail M., primary, Raupov, Rinat K., additional, Suspitsin, Evgeny N., additional, Isupova, Eugenia A., additional, Gaidar, Ekaterina V., additional, Gabrusskaya, Tatyana V., additional, Kaneva, Maria A., additional, Snegireva, Ludmila S., additional, Likhacheva, Tatyana S., additional, Miulkidzhan, Rimma S., additional, Kosmin, Artem V., additional, Tumakova, Anastasia V., additional, Masalova, Vera V., additional, Dubko, Margarita F., additional, Kalashnikova, Olga V., additional, Aksentijevich, Ivona, additional, and Chasnyk, Vyacheslav G., additional

Published
2022
Full Text
View/download PDF

6. FRI0561 COMPARISON OF INITIAL PRESENTATIONS BETWEEN JUVENILE IDIOPATHIC ARTHRITIS CHILDREN WITH SYSTEMIC ONSET WITH NON-BIOLOGIC MONOCYCLIC AND PERSISTENT COURSES

Author

Kostik, Mikhail, primary, Rumyantseva, Maria, additional, Isupova, Eugenia, additional, Chikova, Irina, additional, Dubko, Margarita, additional, Masalova, Vera, additional, Snegireva, Ludmila, additional, Kornishina, Tatiana, additional, Likhacheva, Tatiana, additional, Gaidar, Ekaterina, additional, Santimov, Andrey, additional, and Kalashnikova, Olga, additional

Published
2019
Full Text
View/download PDF

7. AB1000 THE SURVIVAL OF METHOTREXATE IN JUVENILE IDIOPATHIC ARTHRITISCHILDREN AFTER DURING FIRST BIOLOGIC TREATMENT

Author

Raupov, Rinat, primary, Sorokina, Lubov, additional, Korin, Yuri, additional, Avrusin, Ilya, additional, Orlova, Elizaveta, additional, Gaidar, Ekaterina, additional, Dubko, Margarita, additional, Masalova, Vera, additional, Likhacheva, Tatiana, additional, Snegireva, Ludmila, additional, Isupova, Eugenia, additional, Kornishina, Tatiana, additional, Kalashnikova, Olga, additional, and Kostik, Mikhail, additional

Published
2019
Full Text
View/download PDF

8. ETANERCEPT TREATMENT RESULTS IN CHILDREN WITH NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: REMISSION, RECRUDESCENCE, AND ADVERSE EVENTS. RETROSPECTIVE COHORT STUDY

Author

Kostik, Mikhail M., primary, Chikova, Irina A., additional, Isupova, Eugenia A., additional, Likhacheva, Maria N., additional, Likhacheva, Tatyana S., additional, Dubko, Margaruta F., additional, Masalova, Vera V., additional, Snegireva, Ludmila S., additional, Gaidar, Ekaterina V., additional, Kalashnikova, Olga V., additional, and Chasnyk, Vyacheslav G., additional

Published
2018
Full Text
View/download PDF

9. Proteomic Profile of Tears for the Diagnosis of Uveitis Associated with Juvenile Idiopathic Arthritis: Setting Targets to Achieve Results

Author

Chasnyk, Vyacheslav G, primary, Gaidar, Ekaterina V, additional, Kononov, Anatolii Viktorovich, additional, Ammosova, Tatyana, additional, Hynes, Alla, additional, Dubko, Margarita F, additional, Kostik, Mikhail M, additional, Nikitina, Tatiana N, additional, Serogodskaia, Elena D, additional, Kalashnikova, Olga V, additional, Masalova, Vera V, additional, Snegireva, Ludmila S, additional, Keltsev, Vladimir A, additional, Grebenkina, Liudmila I, additional, Obukhov, Yuri, additional, Lin, Xionghao, additional, and Nekhai, Sergei, additional

Published
2017
Full Text
View/download PDF

10. THU0226 Outcomes of Treatment of Juvenile Idiopathic Arthritis Related Uveitis with TNF-Alpha Inhibitors

Author

Kostik Mikhail Mikhaylovich, Snegireva Ludmila Stepanovna, Masalova Vera Vasilyevna, Hynes Alla, Macijevska Aida Sirradzidinovna, Gaidar Ekaterina Vladimirovna, Serogodskaya Elena Dmitrievna, and Dubko Margarita Fedorovna

Subjects
medicine.medical_specialty, business.industry, Immunology, Chorioretinitis, Arthritis, Episcleritis, Uvea, medicine.disease, General Biochemistry, Genetics and Molecular Biology, Infliximab, Surgery, medicine.anatomical_structure, Rheumatology, Internal medicine, Adalimumab, medicine, Immunology and Allergy, business, Scleritis, Uveitis, medicine.drug
Abstract

Background Uveitis is the inflammation of the uvea by definition, but for a rather long time the term “uveitis” was used to identify inflammation in any part of the eye (retinitis, chorioretinitis, scleritis, episcleritis). According to some authors one of the most common causes of uveitis in childhood is Juvenile Idiopathic Arthritis (JIA). Patients with JIA associated uveitis are usually asymptomatic at early stages. In 20–30% of cases uveitis may occur a few years before joint manifestation. As the result of those two factors we often see the delay in the treatment or not adequate treatment. Early and aggressive treatment of JIA associated uveitis can help better control inflammation and can help to eliminate inflammation before development of irreversible ophthalmic pathology. Objectives The goal of the study was to evaluate the efficacy of two anti-TNF-alpha biological agents: Adalimumab (ADA, humanized monoclonal anti-TNF-alpha antibody) and Infliximab (INF, chimeric monoclonal antibody that binds both circulating and membrane-bound TNF-alpha receptors) in the treatment of uveitis, associated with Juvenile idiopathic Arthritis (JIA). The incidence of eye involvement in JIA can be as high as 10–20%. Methods Thirty-seven children with aggressive forms of JIA with uveitis who failed immunosuppressive agents were enrolled in the study. The age of the patients at the beginning of anti-TNF-alpha treatment ranged from 5 to 17 years. All patients were divided into two groups: one group received ADA (40 mg sc every 2 weeks), and the other group was received INF (iv 5–6 mg/kg at week 0–2-6 and after every 8 weeks). Duration of treatment was 3–48 months. The efficacy of treatment was assessed by reduction of flare-ups, reduction of topical and systemic steroids, immunosuppressive drugs and reduction of activity of uveitis. Results In ADA group the remission was observed in 61% of cases, reduction of number of flare-ups was in 18% and in 14% we saw worsening of the disease due to discontinuation of non-biological drug. In INF group remission was in 78% and in 22% of the cases no improvement. The remission of uveitis was achieved in 0.5 - 4 months from the starting of ADA. Topical steroids was tapered within 1.5–3 months and none of the patient required regional injections of steroids. Therapy with ADA permitted to cease non-biological immunosuppressive agents, especially in children who received simultaneously 2 non-biological agents. Conclusions Our experience in ADA treatment of uveitis shows good result in control of uveitis independent from the severity of the disease and despite it was used as a first-, second- or third-line agent among the biologics. The speed of remission in patients with JIA associated uveitis treated with ADA and INF depends on the severity of uveitis, the time between the beginning of the disease and administration of immunosuppressive therapy. This study needs to be continued to enroll more patients and to increase the follow-up time to evaluate the long-term efficacy and safety of anti-TNF-alpha agents in JIA associated uveitis. Disclosure of Interest None declared

Published
2016

12. A128: Hierarchical Clustering Methodology for Exploration of Proteomic Profile in Tears: Seeking for Markers of Uveitis Associated With Juvenile Idiopathic Arthritis

Author

Nekhai, Sergei, primary, Hynes, Alla, additional, Ammosova, Tatiana, additional, Obukhov, Yuri, additional, Gaidar, Ekaterina, additional, Kononov, Anatoly, additional, Dubko, Margarita, additional, Nikitina, Tatiana, additional, Serogodskaia, Elena, additional, Kostik, Mikhail, additional, Kalashnikova, Olga, additional, Masalova, Vera, additional, Snegireva, Ludmila, additional, and Chasnyk, Vyacheslav, additional

Published
2014
Full Text
View/download PDF

13. Initial Respiratory System Involvement in Juvenile Idiopathic Arthritis with Systemic Onset Is a Marker of Interstitial Lung Disease: The Results of Retrospective Cohort Study Analysis.

Author

Belozerov KE, Isupova EA, Solomatina NM, Gaidar EV, Kaneva MA, Chikova IA, Kalashnikova O, Kuznetsova AA, Ivanov DO, and Kostik MM

Abstract

Background: Pulmonary involvement in systemic juvenile idiopathic arthritis (SJIA) is a rare but dangerous complication. The main risk factors are already known, such as macrophage activation syndrome, a refractory course of systemic juvenile arthritis, infusion reaction to interleukin 1 and/or interleukin 6 blockers, trisomy 21, and eosinophilia. However, information about respiratory system involvement (RSI) at the onset of SJIA is scarce. Our study aimed to evaluate the specific features of children with SJIA with RSI and their outcomes. Methods: In a single-center retrospective cohort study, we compared the information from the medical records of 200 children with SJIA according to ILAR criteria or SJIA-like disease (probable/possible SJIA) with and without signs of RSI (dyspnea, shortness of breath, pleurisy, acute respiratory distress syndrome, and interstitial lung disease (ILD)) at the disease onset and evaluated their outcomes (remission, development of chronic ILD, clubbing, and pulmonary arterial hypertension). Results: A quarter (25%) of the SJIA patients had signs of the RSI at onset and they more often had rash; hepato- and splenomegaly; heart (pericarditis, myocarditis), central nervous system, and kidney involvement; hemorrhagic syndrome; macrophage activation syndrome (MAS, 44.4% vs. 9.0%, p = 0.0000001); and, rarely, arthritis with fewer active joints, compared to patients without RSI. Five patients (10% from the group having RSI at the onset of SJIA and 2.5% from the whole SJIA cohort) developed fibrosing ILD. All of them had a severe relapsed/chronic course of MAS; 80% of them had a tocilizumab infusion reaction and further switched to canakinumab. Unfortunately, one patient with Down's syndrome had gone. Conclusion: Patients with any signs of RSI at the onset of the SJIA are required to be closely monitored due to the high risk of the following fibrosing ILD development. They required prompt control of MAS, monitoring eosinophilia, and routine checks of night oxygen saturation for the prevention/early detection of chronic ILD.

Published
2024
Full Text
View/download PDF

14. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use.

Author

Kostik MM, Gaidar EV, Hynnes AY, Dubko MF, Masalova VV, Snegireva LS, Chikova IA, Isupova EA, Nikitina TN, Serogodskaya ED, Kalashnikova OV, Ravelli A, and Chasnyk VG

Subjects
Age Factors, Arthritis, Juvenile diagnosis, Arthritis, Juvenile immunology, Child, Child, Preschool, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Male, Proportional Hazards Models, Risk Factors, Russia, Time Factors, Treatment Outcome, Uveitis diagnosis, Uveitis immunology, Antirheumatic Agents therapeutic use, Arthritis, Juvenile drug therapy, Methotrexate therapeutic use, Uveitis prevention & control
Abstract

Objectives: To re-evaluate the ability of methotrexate (MTX) to prevent the onset of uveitis in Russian children with juvenile idiopathic arthritis (JIA)., Methods: The clinical charts for all consecutive patients who received a stable management for at least 2 years with or without MTX were reviewed. Patients who were given systemic medications other than MTX (except NSAID) and patients with systemic arthritis, rheumatoid factor-positive arthritis, or enthesitis-related arthritis were excluded. Each patient was examined after at least a 2-year follow-up period after the first visit to establish whether uveitis had occurred., Results: A total of 281 patients with a median disease duration of 3.8 years were included. 191 patients (68%) were treated with MTX. During the observation period, 64 patients (22.8%) developed uveitis, a median of 1.6 year after disease onset. The frequency of uveitis was lower in MTX-treated than in MTX-untreated patients (11.5% vs. 46.7%, respectively, OR=6.7 (95%CI:3.7-12.3), p=0.0000001). Survival analysis confirmed that patients treated with MTX had a lower probability of developing uveitis (HR=4.35, p=0.000001). In subgroup analysis it was shown that MTX was more preventive in boys than in girls, and in patients with JIA onset age of over 5 years compared to those with disease onset less than 5 years. The data of survival analysis of MTX prevention has shown that benefits do not depend on the number of active joints and ANA status., Conclusions: MTX therapy may prevent the onset of uveitis in children with JIA. Further randomised controlled trials are required to confirm our results.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results